News

  • HPV9 vaccine offers broader protection and saves healthcare costs in the long run
    HPV9 vaccine offers broader protection and saves healthcare costs in the long run Since 2022, girls and boys in the Netherlands have been eligible to receive the HPV vaccine, which provides preventive protection against six types of cancer. However, even stronger protection is possible with the more expensive HPV9 vaccine. This version protects against nine strains of the virus, which not only cause cancer but can also lead to genital and respiratory warts. Researchers at Amsterdam UMC have now calculated that investing in this more comprehensive vaccine will pay off over time. It reduces unnecessary suffering as well as the healthcare and screening costs associated with diseases the HPV9 vaccine can prevent. The researchers therefore advocate for the inclusion of HPV9 in the national vaccination program.
  • In the spotlight June 2025: AI&I Prizes, Grants, and Appointments
    In the spotlight June 2025: AI&I Prizes, Grants, and Appointments Recently, several prestigious prizes and grants have been awarded to our AI&I members Brent Appelman, Dr. Astrid Hendriks and Prof. Sietze Reitsma. Learn more about these accomplished individuals and their projects in the article below!
  • Amsterdam Impact Award for APH researcher Tessa Roseboom
    Amsterdam Impact Award for APH researcher Tessa Roseboom APH researcher Tessa Roseboom receives the Impact Award 2025. This award is presented to distinguished researchers who make a meaningful contribution to society.